|
Post by lakers on Jun 3, 2016 2:02:50 GMT -5
|
|
|
Post by LosingMyBullishness on Jun 3, 2016 5:48:58 GMT -5
That's bad. Too fast and too easy to overdose according to the article. Think about the potential news: 'Ingenious singer died yesterday with the dreamboat still between his lips..Medics stated: It was too fast, we couldnt bring him back.' Or another one ' he was a diabetic..we didnt know he was an addict and that it was Fentanyl he was inhaling'
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jun 3, 2016 6:33:05 GMT -5
That's bad. Too fast and too easy to overdose according to the article. Think about the potential news: 'Ingenious singer died yesterday with the dreamboat still between his lips..Medics stated: It was too fast, we couldnt bring him back.' Or another one ' he was a diabetic..we didnt know he was an addict and that it was Fentanyl he was inhaling' I am sure the engineering will design different catridges for different uses to solve that issues... Different shaped catridges and corresponding shaped holder in dreamboat
|
|
|
Post by kball on Jun 3, 2016 7:14:41 GMT -5
Trying to decide if it will be really easy or really hard to find volunteers for study.
|
|
|
Post by peppy on Jun 3, 2016 7:18:46 GMT -5
|
|
|
Post by mnholdem on Jun 3, 2016 8:00:37 GMT -5
1. (US20150150980) METHODS AND COMPOSITIONS FOR TREATING PAIN
BACKGROUND
Acute pain is characterized by a sudden onset and relatively short duration, and is generally treated with opioid analgesics like morphine. Morphine and similar opioid analgesics suppress the perception of pain by reducing the number of pain sensations sent by the nervous system and the brain's reaction to those pain signals. Current opioid therapy using morphine and like compounds are effective to treat pain but the side effects they produce such as addiction, somnolence, tolerance, respiratory depression, and constipation limit their clinical use.
...Therefore, there is still a need in the medical art to develop new treatments for pain which would facilitate patient therapy and reduce or eliminate unwanted side effects. Additionally, there is a need for the identification and development of new compounds and compositions that do not cross the blood-brain barrier and effectively alleviate pain without activating opioid receptors in the central nervous system.
DETAILED DESCRIPTION
Disclosed are methods and compositions for treating pain that facilitate delivery of the pain medication while reducing unwanted side effects, such as, for example, addiction, somnolence, tolerance, respiratory depression, and constipation, and the like.
---
The source of this information?
Application Number: 14622660 Application Date: 13.02.2015 Publication Number: 20150150980 Publication Date: 04.06.2015
Applicants: MannKind Corporation Torrey Pines Institute for Molecular Studies Inventors: Andrea Leone-Bay Richard A. Houghten Joseph J. Guarneri Grayson W. Stowell
patentscope.wipo.int/search/en/detail.jsf?docId=US133777752&recNum=1&maxRec=&office=&prevFilter=&sortOption=&queryString=&tab=PCTDescription
---
Since MannKind was successful in having designed (and patented) at least one inhalable opioid that is non-addictive, isn't it reasonable to think that their pulmonary delivery of Fentanyl may have the same non-addictive properties?
Mike Castagna and his team are focusing on pre-launch 2.0 of Afrezza right now, and rightly so, but they mustn't ignore opportunities to promote MannKind's pipeline. The just-released news that Prince's death was caused by an overdose of the painkiller Fentanyl presents an opportunity for MannKind Corporation to remind the medical community that they are in the process of developing a non-addictive version of Fentanyl.
|
|
|
Post by centralcoastinvestor on Jun 3, 2016 8:16:48 GMT -5
1. (US20150150980) METHODS AND COMPOSITIONS FOR TREATING PAIN
BACKGROUND
Acute pain is characterized by a sudden onset and relatively short duration, and is generally treated with opioid analgesics like morphine. Morphine and similar opioid analgesics suppress the perception of pain by reducing the number of pain sensations sent by the nervous system and the brain's reaction to those pain signals. Current opioid therapy using morphine and like compounds are effective to treat pain but the side effects they produce such as addiction, somnolence, tolerance, respiratory depression, and constipation limit their clinical use.
...Therefore, there is still a need in the medical art to develop new treatments for pain which would facilitate patient therapy and reduce or eliminate unwanted side effects. Additionally, there is a need for the identification and development of new compounds and compositions that do not cross the blood-brain barrier and effectively alleviate pain without activating opioid receptors in the central nervous system.
DETAILED DESCRIPTION
Disclosed are methods and compositions for treating pain that facilitate delivery of the pain medication while reducing unwanted side effects, such as, for example, addiction, somnolence, tolerance, respiratory depression, and constipation, and the like.
---
The source of this information?
Application Number: 14622660 Application Date: 13.02.2015 Publication Number: 20150150980 Publication Date: 04.06.2015
Applicants: MannKind Corporation Torrey Pines Institute for Molecular Studies Inventors: Andrea Leone-Bay Richard A. Houghten Joseph J. Guarneri Grayson W. Stowell
patentscope.wipo.int/search/en/detail.jsf?docId=US133777752&recNum=1&maxRec=&office=&prevFilter=&sortOption=&queryString=&tab=PCTDescription
---
Since MannKind was successful in having designed (and patented) at least one inhalable opioid that is non-addictive, isn't it reasonable to think that their pulmonary delivery of Fentanyl may have the same non-addictive properties?
Mike Castagna and his team are focusing on pre-launch 2.0 of Afrezza right now, and rightly so, but they mustn't ignore opportunities to promote MannKind's pipeline. The just-released news that Prince's death was caused by an overdose of the painkiller Fentanyl presents an opportunity for MannKind Corporation to remind the medical community that they are in the process of developing a non-addictive version of Fentanyl.
Well stated. Imagine a pain killer that has little to no opioid side affects. There are so many potential applications for Technosphere, and this is a big one. Thus leading Matt to say that MannKind had an "embarrassment of riches". Now Matt has taken a lot of crap for that comment but I completely understood what he meant. If Afrezza begins to sell well, MannKind could potentially have one of the deepest drug pipelines of any pharma company in the world.
|
|
|
Post by kbrion77 on Jun 3, 2016 8:29:33 GMT -5
1. (US20150150980) METHODS AND COMPOSITIONS FOR TREATING PAIN
BACKGROUND
Acute pain is characterized by a sudden onset and relatively short duration, and is generally treated with opioid analgesics like morphine. Morphine and similar opioid analgesics suppress the perception of pain by reducing the number of pain sensations sent by the nervous system and the brain's reaction to those pain signals. Current opioid therapy using morphine and like compounds are effective to treat pain but the side effects they produce such as addiction, somnolence, tolerance, respiratory depression, and constipation limit their clinical use.
...Therefore, there is still a need in the medical art to develop new treatments for pain which would facilitate patient therapy and reduce or eliminate unwanted side effects. Additionally, there is a need for the identification and development of new compounds and compositions that do not cross the blood-brain barrier and effectively alleviate pain without activating opioid receptors in the central nervous system.
DETAILED DESCRIPTION
Disclosed are methods and compositions for treating pain that facilitate delivery of the pain medication while reducing unwanted side effects, such as, for example, addiction, somnolence, tolerance, respiratory depression, and constipation, and the like.
---
The source of this information?
Application Number: 14622660 Application Date: 13.02.2015 Publication Number: 20150150980 Publication Date: 04.06.2015
Applicants: MannKind Corporation Torrey Pines Institute for Molecular Studies Inventors: Andrea Leone-Bay Richard A. Houghten Joseph J. Guarneri Grayson W. Stowell
patentscope.wipo.int/search/en/detail.jsf?docId=US133777752&recNum=1&maxRec=&office=&prevFilter=&sortOption=&queryString=&tab=PCTDescription
---
Since MannKind was successful in having designed (and patented) at least one inhalable opioid that is non-addictive, isn't it reasonable to think that their pulmonary delivery of Fentanyl may have the same non-addictive properties?
Mike Castagna and his team are focusing on pre-launch 2.0 of Afrezza right now, and rightly so, but they mustn't ignore opportunities to promote MannKind's pipeline. The just-released news that Prince's death was caused by an overdose of the painkiller Fentanyl presents an opportunity for MannKind Corporation to remind the medical community that they are in the process of developing a non-addictive version of Fentanyl.
Well stated. Imagine a pain killer that has little to no opioid side affects. There are so many potential applications for Technosphere, and this is a big one. Thus leading Matt to say that MannKind had an "embarrassment of riches". Now Matt has taken a lot of crap for that comment but I completely understood what he meant. If Afrezza begins to sell well, MannKind could potentially have one of the deepest drug pipelines of any pharma company in the world. Until MNKD has multiple Techno products generating revenue he will always be held accountable for that ill-advised quote. And if I remember correctly he said "suffering" from an embarrassment of riches.
|
|
|
Post by therealisaching on Jun 3, 2016 9:00:06 GMT -5
Since MannKind was successful in having designed (and patented) at least one inhalable opioid that is non-addictive, isn't it reasonable to think that their pulmonary delivery of Fentanyl may have the same non-addictive properties?
Mike Castagna and his team are focusing on pre-launch 2.0 of Afrezza right now, and rightly so, but they mustn't ignore opportunities to promote MannKind's pipeline. The just-released news that Prince's death was caused by an overdose of the painkiller Fentanyl presents an opportunity for MannKind Corporation to remind the medical community that they are in the process of developing a non-addictive version of Fentanyl.
This is MNKD 2.0. Instead of a drug development/manufacturing company, we are evolving into a full fledged pharma. Jurgen played his role in developing the company & now Mike C is leading the commericialization. This year will be about creating the baseline. Afrezza without the dropout rate should have been a $20-40MM 1st year product, per Mike. With the framework they've set up that's where we are headed. I'm considering this year one. This would exceed analysts original revenue estimates.
From a 5/15 RBC analyst report
Afrezza US Sales 1Q:15A 2Q:15E 3Q:15E 4Q:15E 2015E 2016E 2017E 2018E 2019E 2020E 2021E 2022E 2023E Afrezza US Sales - - - - - - 1.1 1.0 1.5 1.4 5.1 118.4 192.0 341.6 539.0 1,081.7 1,172.5 1,271.0 1,377.9
Once done it takes all the bk risk out of the equation. SP will be above $1.5 and the warrants will be exercising adding an additional $50MM. While any of the other catalysts would be nice, a $100-$200MM revenue company (for starters) isnt going anywhere and will have better options on financing going forward.
I look forward to the day when Mike C's sales force is taking a crack at Mylan's $1BB epinephrine business with other items like a non-addictive version of Fentanyl in the well.
I realize this is pie in the sky and for the other drugs we are looking at a much longer term. When I hear Mike C talk about pediatrics using Afrezza and creating a generational change over a 20 year term it really turns my head.
Go ahead, give Mike another listen or listen for the first time if you havent. vimeo.com/167332167 He picks up around the 20 minute mark.
So thank you Olivier Brandicourt for not wanting to deal with inhaled insulin.
|
|
|
Post by kbrion77 on Jun 3, 2016 10:05:26 GMT -5
Matt or Ray should be working on getting a plug by any investing column, "Mannkind working on a non-addictive opioid, the drug that killed Prince".
|
|
|
Post by brotherm1 on Jun 3, 2016 13:58:32 GMT -5
Since MannKind was successful in having designed (and patented) at least one inhalable opioid that is non-addictive, isn't it reasonable to think that their pulmonary delivery of Fentanyl may have the same non-addictive properties?
Mike Castagna and his team are focusing on pre-launch 2.0 of Afrezza right now, and rightly so, but they mustn't ignore opportunities to promote MannKind's pipeline. The just-released news that Prince's death was caused by an overdose of the painkiller Fentanyl presents an opportunity for MannKind Corporation to remind the medical community that they are in the process of developing a non-addictive version of Fentanyl.
This is MNKD 2.0. Instead of a drug development/manufacturing company, we are evolving into a full fledged pharma. Jurgen played his role in developing the company & now Mike C is leading the commericialization. This year will be about creating the baseline. Afrezza without the dropout rate should have been a $20-40MM 1st year product, per Mike. With the framework they've set up that's where we are headed. I'm considering this year one. This would exceed analysts original revenue estimates.
From a 5/15 RBC analyst report
Afrezza US Sales 1Q:15A 2Q:15E 3Q:15E 4Q:15E 2015E 2016E 2017E 2018E 2019E 2020E 2021E 2022E 2023E Afrezza US Sales - - - - - - 1.1 1.0 1.5 1.4 5.1 118.4 192.0 341.6 539.0 1,081.7 1,172.5 1,271.0 1,377.9
Once done it takes all the bk risk out of the equation. SP will be above $1.5 and the warrants will be exercising adding an additional $50MM. While any of the other catalysts would be nice, a $100-$200MM revenue company (for starters) isnt going anywhere and will have better options on financing going forward.
I look forward to the day when Mike C's sales force is taking a crack at Mylan's $1BB epinephrine business with other items like a non-addictive version of Fentanyl in the well.
I realize this is pie in the sky and for the other drugs we are looking at a much longer term. When I hear Mike C talk about pediatrics using Afrezza and creating a generational change over a 20 year term it really turns my head.
Go ahead, give Mike another listen or listen for the first time if you havent. vimeo.com/167332167 He picks up around the 20 minute mark.
So thank you Olivier Brandicourt for not wanting to deal with inhaled insulin.
$118 million in 2016? Am I reading this accurately? Looks like you spent a lot of time with your analysis. How did you derive these numbers though?
|
|
|
Post by lakon on Jun 3, 2016 15:19:38 GMT -5
1. (US20150150980) METHODS AND COMPOSITIONS FOR TREATING PAIN ... Application Number: 14622660 Application Date: 13.02.2015 Publication Number: 20150150980 Publication Date: 04.06.2015 ...
Applicants: MannKind Corporation Torrey Pines Institute for Molecular Studies
---
Since MannKind was successful in having designed (and patented) at least one inhalable opioid that is non-addictive, isn't it reasonable to think that their pulmonary delivery of Fentanyl may have the same non-addictive properties?
Mike Castagna and his team are focusing on pre-launch 2.0 of Afrezza right now, and rightly so, but they mustn't ignore opportunities to promote MannKind's pipeline. The just-released news that Prince's death was caused by an overdose of the painkiller Fentanyl presents an opportunity for MannKind Corporation to remind the medical community that they are in the process of developing a non-addictive version of Fentanyl.
No, it is not reasonable to think that their Fentanyl candidate is non-addictive. MNKD and Torrey Pines have a non-addictive pain relieving new API candidate based on a shellfish from what I recall. They also discuss the possibility of various peptide candidates. They discuss non-opiates that act by binding to opioid receptors or other possible candidates that are non-opioid with a different action. MNKD management stated on multiple occasions that new API candidates are on hold due to significant financial and time consuming commitments to bringing new API's to market. Think another 10-15 year endeavor or longer. I mean human insulin is not a drug. It is a naturally occurring human hormone. It is an already approved API. Yet, it took MNKD and the FDA a very long time to get TI approved as Afrezza. It is very clear that the FDA is risk averse at the very least, and it can be argued that they are quite selective in their approval process. Do not think that safety for the patient is the primary reason for their selectivity. Anyway, MNKD said that they would focus on already approved API candidates that could be formulated into a Technosphere candidate for inhalation, or presumably other paths of administration, as disclosed by other patents (e.g., oral, insufflation, or injection). I never heard MNKD state anything about a non-addictive Fentanyl, and I don't think it's possible. Some were very negative to the suggestion of Fentanyl for this very reason. What I think MNKD can do is provide a better solution than is currently available. They may even be able to use the FDA and DEA to take competitors off the market in favor of a MNKD solution that is significantly safer and more difficult to abuse. This direction is the path of least resistance. Improve upon the already existing solutions until enough time and money can be spent to get a far better non-addictive new API approved. This capability of Technosphere is one of the reasons that I am so impressed with MNKD as an investment. They can improve upon generics to develop a significant generic business through proprietary means. They can add new API's when appropriate (i.e., when time and money are available). Therefore, MNKD is really moving in the right direction to become a big pharma with a strong pipeline and commercial organization.
|
|
|
Post by peppy on Jun 3, 2016 15:34:03 GMT -5
1. (US20150150980) METHODS AND COMPOSITIONS FOR TREATING PAIN ... Application Number: 14622660 Application Date: 13.02.2015 Publication Number: 20150150980 Publication Date: 04.06.2015 ...
Applicants: MannKind Corporation Torrey Pines Institute for Molecular Studies
---
Since MannKind was successful in having designed (and patented) at least one inhalable opioid that is non-addictive, isn't it reasonable to think that their pulmonary delivery of Fentanyl may have the same non-addictive properties?
Mike Castagna and his team are focusing on pre-launch 2.0 of Afrezza right now, and rightly so, but they mustn't ignore opportunities to promote MannKind's pipeline. The just-released news that Prince's death was caused by an overdose of the painkiller Fentanyl presents an opportunity for MannKind Corporation to remind the medical community that they are in the process of developing a non-addictive version of Fentanyl.
No, it is not reasonable to think that their Fentanyl candidate is non-addictive. MNKD and Torrey Pines have a non-addictive pain relieving new API candidate based on a shellfish from what I recall. They also discuss the possibility of various peptide candidates. They discuss non-opiates that act by binding to opioid receptors or other possible candidates that are non-opioid with a different action. MNKD management stated on multiple occasions that new API candidates are on hold due to significant financial and time consuming commitments to bringing new API's to market. Think another 10-15 year endeavor or longer. I mean human insulin is not a drug. It is a naturally occurring human hormone. It is an already approved API. Yet, it took MNKD and the FDA a very long time to get TI approved as Afrezza. It is very clear that the FDA is risk averse at the very least, and it can be argued that they are quite selective in their approval process. Do not think that safety for the patient is the primary reason for their selectivity. Anyway, MNKD said that they would focus on already approved API candidates that could be formulated into a Technosphere candidate for inhalation, or presumably other paths of administration, as disclosed by other patents (e.g., oral, insufflation, or injection). I never heard MNKD state anything about a non-addictive Fentanyl, and I don't think it's possible. Some were very negative to the suggestion of Fentanyl for this very reason. What I think MNKD can do is provide a better solution than is currently available. They may even be able to use the FDA and DEA to take competitors off the market in favor of a MNKD solution that is significantly safer and more difficult to abuse. This direction is the path of least resistance. Improve upon the already existing solutions until enough time and money can be spent to get a far better non-addictive new API approved. This capability of Technosphere is one of the reasons that I am so impressed with MNKD as an investment. They can improve upon generics to develop a significant generic business through proprietary means. They can add new API's when appropriate (i.e., when time and money are available). Therefore, MNKD is really moving in the right direction to become a big pharma with a strong pipeline and commercial organization. quote; it is not reasonable to think that their Fentanyl candidate is non-addictive
agreed. Addiction, thought to be a dopamine hit to the nucleus accumbens
I have had oxycotin after surgery. I have no clue what the big addiction is. Guess it wasn't what delivered dopamine to MY nucleus accumbens. Look how deep addiction hits. It hit Prince, right between the eyes. en.wikipedia.org/wiki/Limbic_system
|
|
|
Post by mnholdem on Jun 3, 2016 18:34:44 GMT -5
One of the reasons I appreciate ProBoards so much is the number of members who understand how drugs work. After reading the MannKind-Torrie Pines patent of pulmonary delivery of API that act on the opioid receptors in the brain followed by reading how fentanyl also blocks opioid receptors in the brain (source WebMD) I made an apparently erroneous assumption that they would be similar in their addictive properties. It appears that these two painkillers may block the opioid receptors in the brain, but that's where the similarities end.
Thank you for pointing out the distinctions between the two.
My thought process was that by taking advantage of current news, such as Prince's death, pharmaceutical giants may take notice of MannKind pipeline and mgt would increase our visibility to potential future partners who may want a piece of the action in developing Fentanyl and/or other drug candidates.
|
|
|
Post by lakers on Jun 3, 2016 23:32:03 GMT -5
|
|